Health and Global Policy Institute (HGPI) has offered policy recommendations and taken a number of other activities to promote patient and public involvement (PPI) in policy development process, under our stated mission of “Achieving citizen-centered health policy.” Recently, initiatives for PPI in processes of health policy development are now being advanced at both the national Government and local level at councils. However, new issues have been recognized consequently, which include lack of the diversities in and the number of individuals who desire to be involved. Based on our recognition of these issues, our PPI Support Project this year aims to promote the involvement of diverse patient and public representatives into policy development process.

In the 2nd advisory board meeting, advisory board members from industries, government officials, academia and civil society discussed design of policy making process that reflects the voices of diverse patients and citizens and measures to secure human resources for patient and citizen engagement.

For more details, please find the PDF document attached at the bottom.

[Event Overview]

• Date & time: Tuesday, October 3, 2023; from 17:30 to 19:30 JST
• Format: Hybrid (Zoom conferencing system and in-person participation at the venue)

Advisory Board Members (Titles omitted; in Japanese alphabetical order by last name, absent members included)

Kyoko Ama (Representative, Children and Healthcare Project; Fellow, HGPI)
Shinsuke Amano (Chair, The Japan Federation of Cancer Patient Groups; CEO, Group Nexus Japan)
Etsuko Aruga (Professor, Department of Palliative Medicine, Teikyo University School of Medicine)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Takeshi Shukunobe (President and CEO, PPeCC)
Kazuyuki Suzuki (Senior Lead, Patient Engagement Group, Strategy & Execution, Novartis Pharma K.K.)
Yasuhiro Sensho (CEO, SENSHO-GUMI, Co., Ltd.; Former Director-General, MHLW)
Teppei Maeda (Lawyer, Maeda & Unosawa Law Offices; Representative, Medical Basic Act Community)
Kaori Muto (Professor, Department of Public Policy Studies, Institute of Medical Science, University of Tokyo)
Akira Morita (Representative Director, Next Generation Fundamental Policy Research Institute (NFI))
Ikuko Yamaguchi (Chief Director, Consumer Organization for Medicine and Law (COML))
Risa Yamazaki (Public Affairs Group, External Affairs Department, Chugai Pharmaceutical Co., LTD.)